Recap: Akebia Therapeutics Q1 Earnings

 

Shares of Akebia Therapeutics AKBA fell 1.0% in pre-market trading after the company reported Q1 results.

Quarterly Results

Earnings per share rose 4.26% year over year to ($0.45), which missed the estimate of ($0.36).

Revenue of $52,304,000 decreased by 40.88% from the same period last year, which beat the estimate of $42,840,000.

Outlook

Earnings guidance hasn't been issued by the company for now.

Revenue guidance hasn't been issued by the company for now.

Details Of The Call

Date: May 10, 2021

Time: 09:00 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/d9mze5u6

Technicals

Company's 52-week high was at $13.71

52-week low: $2.09

Price action over last quarter: down 10.69%

Company Profile

Akebia Therapeutics Inc is a biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is Vadadustat, an oral therapy, which is used for the treatment of anemia related to chronic kidney disease in non-dialysis and dialysis patients. The company is also developing a HIF-based portfolio of product for the treatment of anemia. Geographically, all the business activity is functioned through the region of United States.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsBZI-Recaps
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!